Product Description
BA1301 for injection is the Group's first novel ADC candidate that targets Claudin 18.2. It employs a site-specific conjugation technology to connect the cytotoxic payload with a monoclonal antibody that targets Claudin 18.2. This enables the cytotoxic payload to be directed to the tumor site through the targeting characteristics of the antibody. Such design reduces the toxic side effects of the cytotoxic payload, thus improving the therapeutic window, while retaining its tumor-killing effect. (Sourced from: https://www.boan-bio.com/en/uploads/2023-01/11/_1673420140_37ahis.pdf)
Mechanisms of Action: CLDN18.2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shandong Boan Biotechnology Co., Ltd
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06927349 |
BA1301/CT-CHN-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-06-30 |
2025-04-16 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|